Drugs & Targets MD Anderson and ARTIDIS form strategic alliance to advance nanomechanical technology platform October 07, 2022Vol.48 No.36
Drugs & Targets Merck’s Keytruda receives four approvals in Japan, including in high-risk early-stage TNBC September 30, 2022Vol.48 No.35
Drugs & Targets FDA approves Retevmo for locally advanced or metastatic RET fusion-positive solid tumors, NSCLC September 23, 2022Vol.48 No.34
Drugs & Targets FDA approves Pedmark to reduce the risk of ototoxicity associated with cisplatin for localized pediatric solid tumors September 23, 2022Vol.48 No.34
Drugs & Targets Foundation Medicine and Day One Biopharmaceuticals form collaboration focused on pediatric cancer care September 23, 2022Vol.48 No.34
Drugs & Targets MSK researchers present predictive findings from first use of Mission Bio’s scMRD assay for AML September 23, 2022Vol.48 No.34
Drugs & Targets FDA issues safety alert for squamous cell carcinoma and various lymphomas in scar tissue around breast implants September 16, 2022Vol.48 No.33
Drugs & Targets Roche’s VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo September 16, 2022Vol.48 No.33
Drugs & Targets MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D September 16, 2022Vol.48 No.33
Drugs & Targets OU Health Stephenson Cancer Center joins Caris’ Precision Oncology Alliance September 16, 2022Vol.48 No.33
